A prospective non-randomised dual arm longitudinal cohort of people with acute or newly acquired Hepatitis C within which all subjects will be given the option of undergoing treatment involving a 24 week course of pegylated interferon monotherapy (180mcg/wk) at entry to study

Trial Profile

A prospective non-randomised dual arm longitudinal cohort of people with acute or newly acquired Hepatitis C within which all subjects will be given the option of undergoing treatment involving a 24 week course of pegylated interferon monotherapy (180mcg/wk) at entry to study

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Therapeutic Use
  • Acronyms ATAHC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top